tiprankstipranks
Kiniksa Pharmaceuticals (KNSA)
NASDAQ:KNSA
US Market

Kiniksa Pharmaceuticals (KNSA) Financial Statements

414 Followers

Kiniksa Pharmaceuticals Financial Overview

Kiniksa Pharmaceuticals's market cap is currently ―. The company's EPS TTM is $0.108; its P/E ratio is 196.03; Kiniksa Pharmaceuticals is scheduled to report earnings on July 31, 2024, and the estimated EPS forecast is
lt;0.01. See an overview of income statement, balance sheet, and cash flow financials.
Dec 23Sep 23Jun 23Mar 23Dec 22
Income Statement-
Total Revenue$ 83.39M$ 67.05M$ 54.49M$ 48.34M$ 61.88M
Gross Profit$ 113.40M$ 57.96M$ 63.77M$ 41.31M$ 47.65M
EBIT-$ -8.50M$ -1.24M$ -9.36M$ 7.30M
EBITDA--$ -1.79M$ -9.83M$ 7.70M
Net Income Common Stockholders$ 25.24M$ 20.77M$ 14.97M$ -12.27M$ 4.46M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 206.37M$ 201.08M$ 184.99M$ 187.49M$ 190.61M
Total Assets$ 526.32M$ 483.06M$ 484.33M$ 442.86M$ 459.67M
Total Debt$ 12.26M$ 12.96M$ 13.52M$ 5.62M$ 5.92M
Net Debt$ -194.11M$ -188.12M$ -171.47M$ -181.88M$ -184.69M
Total Liabilities$ 87.48M$ 77.94M$ 72.68M$ 52.77M$ 459.66M
Stockholders Equity$ 438.84M$ 405.13M$ 411.65M$ 390.10M$ 396.14M
Cash Flow-
Free Cash Flow--$ -3.78M$ -4.29M$ -11.53M
Operating Cash Flow$ 4.33M$ 16.99M$ -3.74M$ -4.27M$ -11.58M
Investing Cash Flow$ -14.89M$ -12.28M$ 35.53M$ -37.92M$ -42.66M
Financing Cash Flow$ 695.00K$ 552.00K$ 158.00K$ 90.00K$ 1.19M
Currency in USD

Kiniksa Pharmaceuticals Earnings and Revenue History

Kiniksa Pharmaceuticals Debt to Assets

Kiniksa Pharmaceuticals Cash Flow

Kiniksa Pharmaceuticals Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis